OnePin Peptide Library · Longevity
Dasatinib+Quercetin
D+Q · Senolytic Stack · Dasatinib Quercetin
Dasatinib plus Quercetin (D+Q) is a senolytic combination therapy developed at the Mayo Clinic by Drs. James Kirkland and Tamara Tchkonia. Dasatinib is an FDA-approved tyrosine kinase inhibitor (brand name Sprycel) used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Quercetin is a naturally occurring flavonoid found in fruits, vegetables, and supplements. Together, they selectively target and eliminate senescent cells - damaged cells that have stopped dividing but resist apoptosis and secrete a toxic mix of inflammatory factors known as the senescence-associated secretory phenotype (SASP).,The rationale for combining these two agents is their complementary senolytic activity across different cell types. Dasatinib is more effective against senescent human preadipocytes (fat cell precursors), while quercetin is more potent against senescent human endothelial cells and bone marrow stem cells. Together, they cover a broader range of senescent cell types than either agent alone. The combination was first published in 2015 (Zhu et al., Aging Cell) and has since been tested in multiple human pilot studies.,D+Q is administered intermittently (typically 2-3 consecutive days per month), based on the principle that senescent cells take weeks to reaccumulate after clearance, so continuous dosing is unnecessary. Human pilot trials at Mayo Clinic have shown promising results in idiopathic pulmonary fibrosis (IPF), diabetic kidney disease, and frailty in elderly individuals. However, large Phase III trials have not yet been completed, and the combination is not FDA-approved for any anti-aging indication.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Dasatinib inhibits multiple tyrosine kinases (Src family kinases, BCR-ABL, ephrin receptors) that senescent cells depend on for survival signaling. By blocking these pro-survival pathways (particularly the Src/PI3K/AKT axis), dasatinib pushes senescent preadipocytes and other mesenchymal senescent cells toward apoptosis.,Quercetin inhibits PI3K, serpins (particularly PAI-2), and BCL-2 family anti-apoptotic proteins that protect senescent endothelial cells and bone marrow stem cells from programmed cell death. It also has broad anti-inflammatory and antioxidant properties that complement its senolytic activity.,The combination exploits the fact that different senescent cell types rely on different anti-apoptotic networks (SCAPs - Senescent Cell Anti-apoptotic Pathways). By targeting multiple SCAPs simultaneously, D+Q achieves broader senescent cell clearance than either compound alone.
Dasatinib inhibits multiple tyrosine kinases (Src family kinases, BCR-ABL, ephrin receptors) that senescent cells depend on for survival signaling. By blocking these pro-survival pathways (particularly the Src/PI3K/AKT axis), dasatinib pushes senescent preadipocytes and other mesenchymal senescent cells toward apoptosis.,Quercetin inhibits PI3K, serpins (particularly PAI-2), and BCL-2 family anti-apoptotic proteins that protect senescent endothelial cells and bone marrow stem cells from programmed cell death. It also has broad anti-inflammatory and antioxidant properties that complement its senolytic activity.,The combination exploits the fact that different senescent cell types rely on different anti-apoptotic networks (SCAPs - Senescent Cell Anti-apoptotic Pathways). By targeting multiple SCAPs simultaneously, D+Q achieves broader senescent cell clearance than either compound alone.
What to expect
Days 1-7: Senescent cell apoptosis initiated during dosing days. SASP factor reduction measurable within days. Possible transient side effects (GI, fatigue) during dosing.
Evidence
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Safe & synergistic
Keep separate
Pharmacokinetics
Storage. Dasatinib: store at room temperature 20-25C (68-77F). Quercetin: store in cool, dry place. No refrigeration needed for either compound in oral form.
Regulatory status
Dasatinib is FDA-approved for CML and Ph+ ALL (not for senolytic use). Quercetin is a dietary supplement (no FDA approval needed). The D+Q senolytic combination is investigational and not approved for any anti-aging indication. Multiple clinical trials ongoing (ClinicalTrials.gov).
Put it to work
Calculate, log & track
Open Dasatinib+Quercetin straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Dasatinib+Quercetin in the app →Go deeper
The guide & community
The complete Dasatinib+Quercetin walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗